Literature DB >> 26113083

Oncogenic G Protein GNAQ Induces Uveal Melanoma and Intravasation in Mice.

Jenny Li-Ying Huang1, Oscar Urtatiz1, Catherine D Van Raamsdonk2.   

Abstract

GNAQ and GNA11 are heterotrimeric G protein alpha subunits, which are mutated in a mutually exclusive pattern in most cases of uveal melanoma, one of the most aggressive cancers. Here we introduce the first transgenic mouse model of uveal melanoma, which develops cancers induced by expression of oncogenic GNAQ(Q209L) under control of the Rosa26 promoter. Disease penetrance is 100% by 3 months of age, with 94% of mice also developing lung tumors. In this model, the Yap protein of the Hippo pathway is activated in the eyes, and blood vessels near the lesions in the head and lungs exhibit melanocytic invasion. While full transcription levels are not necessary for GNAQ(Q209L) to transform mouse melanocytes, we obtained suggestive evidence of a selective advantage for increased GNAQ(Q209L) expression in human tumors. Intriguingly, enforced expression of GNAQ(Q209L) progressively eliminated melanocytes from the interfollicular epidermis in adults, possibly explaining the near absence of GNAQ(Q209) mutations in human epithelial melanomas. The mouse model also exhibited dermal nevi and melanocytic neoplasms of the central nervous system, accompanied by impaired hearing and balance, identifying a novel role for GNAQ in melanocyte-like cells of the inner ear. Overall, this model offers a new tool to dissect signaling by oncogenic GNAQ and to test potential therapeutics in an in vivo setting where GNAQ(Q209L) mutations contribute to both the initiation and metastatic progression of uveal melanoma. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26113083     DOI: 10.1158/0008-5472.CAN-14-3229

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  Circulating extracellular vesicles containing miRNAs may have utility as early biomarkers for cardiac injury.

Authors:  Bethany Doran; Deepak Voora
Journal:  Ann Transl Med       Date:  2016-10

2.  Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma.

Authors:  Dominic Lapadula; Eduardo Farias; Clinita E Randolph; Timothy J Purwin; Dougan McGrath; Thomas H Charpentier; Lihong Zhang; Shihua Wu; Mizue Terai; Takami Sato; Gregory G Tall; Naiming Zhou; Philip B Wedegaertner; Andrew E Aplin; Julio Aguirre-Ghiso; Jeffrey L Benovic
Journal:  Mol Cancer Res       Date:  2018-12-19       Impact factor: 5.852

3.  A G protein-coupled, IP3/protein kinase C pathway controlling the synthesis of phosphaturic hormone FGF23.

Authors:  Qing He; Lauren T Shumate; Julia Matthias; Cumhur Aydin; Marc N Wein; Jordan M Spatz; Regina Goetz; Moosa Mohammadi; Antonius Plagge; Paola Divieti Pajevic; Murat Bastepe
Journal:  JCI Insight       Date:  2019-09-05

4.  Uveal melanoma driver mutations in GNAQ/11 yield numerous changes in melanocyte biology.

Authors:  Dahlia E Perez; Andrea M Henle; Adam Amsterdam; Hannah R Hagen; Jacqueline A Lees
Journal:  Pigment Cell Melanoma Res       Date:  2018-04-06       Impact factor: 4.693

Review 5.  The duality of human oncoproteins: drivers of cancer and congenital disorders.

Authors:  Pau Castel; Katherine A Rauen; Frank McCormick
Journal:  Nat Rev Cancer       Date:  2020-04-27       Impact factor: 60.716

Review 6.  Genetically engineered mouse models of melanoma.

Authors:  Eva Pérez-Guijarro; Chi-Ping Day; Glenn Merlino; M Raza Zaidi
Journal:  Cancer       Date:  2017-06-01       Impact factor: 6.860

7.  Xenograft Mouse Model of Human Uveal Melanoma.

Authors:  Yao Chen; Xiao Liu; Ling Gao; Yongqing Liu
Journal:  Bio Protoc       Date:  2017-11-05

8.  Atypical activation of the G protein Gαq by the oncogenic mutation Q209P.

Authors:  Marcin Maziarz; Anthony Leyme; Arthur Marivin; Alex Luebbers; Prachi P Patel; Zhe Chen; Stephen R Sprang; Mikel Garcia-Marcos
Journal:  J Biol Chem       Date:  2018-10-23       Impact factor: 5.157

Review 9.  From melanocytes to melanomas.

Authors:  A Hunter Shain; Boris C Bastian
Journal:  Nat Rev Cancer       Date:  2016-04-29       Impact factor: 60.716

Review 10.  Hindsight: Review of Preclinical Disease Models for the Development of New Treatments for Uveal Melanoma.

Authors:  Caoimhe Goldrick; Letizia Palanga; Bobby Tang; Grace Mealy; John Crown; Noel Horgan; Susan Kennedy; Naomi Walsh
Journal:  J Cancer       Date:  2021-06-04       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.